ÁñÁ«ÊÓƵ

This phase 1 randomized study assesses the safety and tolerability of zerlasiran, a short interfering RNA targeting hepatic synthesis of apolipoprotein(a), and its effects on serum concentrations of lipoprotein(a), in healthy participants and patients with stable atherosclerotic cardiovascular disease.

This randomized clinical trial evaluates whether testosterone replacement therapy prevents progression from prediabetes to diabetes or induces glycemic remission in middle-aged and older men with hypogonadism.

This prespecified analysis of the Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase (ACL)–Inhibiting Regimen (CLEAR) Outcomes trial investigates if bempedoic acid is associated with a reduction in the total burden of cardiovascular events in patients at high risk for cardiovascular disease.

This randomized clinical trial examines the effects of testosterone replacement therapy on major adverse cardiovascular events in men with hypogonadism.

This randomized clinical trial compares a single dose of lepodisiran vs placebo to assess the safety, tolerability, pharmacokinetics, and effects on lipoprotein(a) concentrations in adults without cardiovascular disease and with lipoprotein(a) serum concentrations of 75 nmol/L or greater at baseline.

This randomized clinical trial examines the effectiveness of testosterone replacement therapy to correct anemia in men with hypogonadism.

This randomized clinical trial assesses the effect of 5 dosages of lorundrostat treatment vs placebo on 8-week systolic blood pressure change among adults with uncontrolled hypertension.

This randomized clinical trial investigates the long-term efficacy of mavacamten in reducing the need for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy.

This phase 1 randomized clinical trial evaluates the safety, tolerability, pharmacokinetics, and exploratory pharmacodynamic biomarker effects of muvalaplin in humans.

This 32-country randomized clinical trial assesses the effects of bempedoic acid on cardiovascular outcomes in statin-intolerant patients receiving bempedoic acid vs placebo for primary prevention of a first major adverse cardiovascular event.

This Viewpoint discusses the concerns about using mineral oil as a placebo.

This matched cohort study investigates whether bariatric surgery is associated with lower cancer risk and mortality in adult patients with a body mass index of 35 or greater who underwent bariatric surgery at a US health system between 2004 and 2017 vs those who did not undergo surgery for their obesity.

This phase 1 study evaluated the safety and tolerability of 4 different doses of a short interfering RNA designed to reduce hepatic production of apolipoprotein(a) and assessed associated changes in plasma concentrations of lipoprotein(a), compared with placebo, among individuals with elevated lipoprotein(a) levels and no known cardiovascular disease.

This cohort study examines weight loss outcomes from surgical and nonsurgical interventions among patients with obesity before and after the COVID-19 outbreak.

This cohort study investigates the association between bariatric surgery and incident major adverse liver outcomes and major adverse cardiovascular events in patients with obesity and biopsy-proven fibrotic NASH without cirrhosis.

This systematic review examines temporal trends of retractions in cardiology literature and assesses their effect.